UTAH MEDICAL PRODUCTS INC (UTMD) Form 8-K — Oct 22, 2026
Utah Medical Products reported 3Q 2026 revenue of $8.6 million, down 12.1% year over year, driven by the loss of its two previously largest customers (PendoTECH and its former China BPM distributor) and a 32.7% drop in Filshie Clip sales. Despite the revenue decline, 3Q net income rose 5.9% to $2.8 million and diluted EPS increased 6.8% to $0.876, helped by lower litigation and intangible amortization expense plus a lower tax rate. Nine-month revenue fell 12.2% to $25.9 million with EPS down 5.3%.
Key figures
- Eps
- 0.876
- Revenue
- 8621000
- Guidance
- Full-year 2026 consolidated sales expected to decline close to 7%
- Net Income
- 2787000
- Total Debt
- 0
- Revenue Yoy
- -12.1%
- Total Assets
- 128501000
- Cash Position
- 85202000
- Shares Outstanding
- 3175006
- Q3 eps yoy
- +6.8%
- Current ratio
- 21.2
- Q3 gross margin
- 56.1%
- Q3 2026 tax rate
- 18.1%
- Q3 2025 revenue k
- 9812
- Q3 2026 revenue k
- 8621
- Dividend per share
- 0.31
- Dividends paid 9m k
- 2963
- Nine month 2026 eps
- 2.537
- Q3 operating margin
- 32.4%
- Q3 net income margin
- 32.3%
- Ttm adjusted ebitda k
- 15269
- Orion acquisition cost k
- 5011
- Nine month 2026 revenue k
- 25873
- Filshie q3 sales decline pct
- -32.7%
- Orion q3 sales contribution k
- 619
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.